OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Discount Codes

  • ACI Conferences
    Orange Book Blog readers save $400 on registration with THE MEDIA PARTNER DISCOUNT
  • CBI Conferences
    Orange Book Blog readers save $400 on registration with Promo Code DTY367

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« ACI "FDA Boot Camp" Conference, Boston, September 22-23 | Main | CBI "Paragraph IV Disputes" Conference, Philadelphia, October 15-16 »

September 21, 2008

ACI "Maximizing Pharmaceutical Patent Life Cycles" Conference, New York, October 15-16

American Conference Institute is holding its ninth annual "Maximizing Pharmaceutical Patent Life Cycles" conference October 15-16 in New York.  According to ACI, this "definitive Hatch-Waxman event provides the crucial information for pharmaceutical patent counsel to cultivate, modify, and enhance a foundation for their life cycle strategies."

The agenda includes many topics covered on Orange Book Blog.  Selected talks include:

  • "Constructing, Adjusting, and Executing a Pharmaceutical Patent Life Cycle Management Plan"
  • "View from the FTC," presented by Saralisa Brau, Health Care Services and Products Division, FTC
  • "Navigating the Complexity of Structuring Patent Settlement Options Between Brand Name and Generic Pharmaceutical Companies"
  • "Eye on the Bench:  Identifying Judicial Trends in Pharmaceutical Patent Cases"
  • "Mastering the Intricacies of the 180-Day Generic Market Exclusivity"
  • "Plotting a Course Into Safe Harbor for Branded Pharma"
  • "View from the FDA," presented by Elizabeth Dickinson, Office of Chief Counsel, FDA
  • "Slicing Through the Complex Spectrum of Declaratory Judgment Actions in Pharmaceutical Patent Cases"
  • "Factoring the Role, Challenges, and Impact of Orange Book Listings and Delistings in Patent Portfolio Management"

In addition, two optional post-conference workshops are offered on October 17th:  a brand name master class entitled "Overpowering the Challenges in Increasing the Pharmaceutical Patent Life Cycle Through Patent Extensions" and a generics master class entitled "Adding Value to Paragraph IV Certifications and Notice Letters."

For more information or to register, please visit the conference website.

Orange Book Blog readers can save $200 by using registration code S.

Comments

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.